Aspirin inhibits platelet activity but does not attenuate experimental atherosclerosis.
We evaluated the antiatherosclerotic potential of aspirin, a platelet inhibitor, in lipid-fed rabbits (0.3% cholesterol diet). Seventy-five male New Zealand white rabbits were divided into treated or control groups. The treated groups were given aspirin by daily gavage for 12 weeks (1 mg/kg, 10 mg/kg, 30 mg/kg, and 60 mg/kg) and 10 rabbits served as controls. Increased bleeding time was observed in the aspirin-treated groups (average, 58 +/- 10 seconds to 75 +/- 17 seconds; p < 0.001). Only high-dose aspirin (60 mg/kg/day) significantly inhibited platelet aggregation (1.04 +/- 0.15 vs 0.67 +/- 0.14; p < 0.05). Seventeen additional rabbits had aortic endothelial injury produced by a balloon catheter. Eight of them were given aspirin (40 mg/kg/day), and the other nine served as controls. The average percent of surface lesions and lesion thickness of the aorta and pulmonary artery were not significantly reduced by aspirin. These results show that at doses that cause antiplatelet effects, aspirin does not attenuate atherosclerosis.
Sun
Y P
YP
Department of Medicine, University of California, San Francisco 94143-0124.
Zhu
B Q
BQ
Sievers
R E
RE
Isenberg
W M
WM
Parmley
W W
WW
D000704:Analysis of Variance; D000800:Angioplasty, Balloon; D000818:Animals; D001011:Aorta / Q000293:injuries / Q000473:pathology; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001760:Bleeding Time; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D011897:Random Allocation; D015430:Weight Gain / Q000187:drug effects
D002791:Cholesterol, Dietary; D002784:Cholesterol; D001241:Aspirin